Blue Earth Therapeutics

Blue Earth Therapeutics

UK - Oxford
Pharmaceutical

Focus: Radiopharmaceuticals

Blue Earth Therapeutics is a life sciences company focused on Radiopharmaceuticals.

Neurology
Funding Stage
SERIES A
Open Jobs
0

Pipeline & Clinical Trials

Fluciclovine
Breast Cancer
N/A
Clinical Trials (1)
NCT03036943Fluciclovine (18F) Imaging of Breast Cancer
N/A
18F-rhPSMA-7.3
Prostate Cancer
N/A
Clinical Trials (1)
NCT07011342Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
N/A
Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT
Patients With Prostate Cancer
N/A
Clinical Trials (1)
NCT03527199Prostate Cancer Patients With Biochemical Recurrence
N/A
F-18 fluciclovine-PET/CT scan
Prostate Adenocarcinoma
N/A
Clinical Trials (1)
NCT03496844Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
N/A
N/A
Clinical Trials (1)
NCT02443571Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
N/A
Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography
Metastatic Intracranial Malignant Neoplasm
N/A
Clinical Trials (1)
NCT0446241918F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain
N/A
Positron Emission Tomography
Prostate Cancer (Adenocarcinoma)
N/A
Clinical Trials (1)
NCT06862856Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
N/A
18F-Fluciclovine
Brain Metastases
N/A
Clinical Trials (1)
NCT06015295A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
N/A
Clinical Trials (1)
NCT07115914PSMA PET for Surveillance After Focal Therapy
N/A
18F-fluciclovine
Advanced Prostate Cancer
Phase 1
Clinical Trials (1)
NCT06062745Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Phase 1
Biopsy of Prostate
Prostate Carcinoma
Phase 1
Clinical Trials (1)
NCT07164027Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
Phase 1
Axumin, Intravenous Solution
Glioma Glioblastoma Multiforme
Phase 1
Clinical Trials (1)
NCT03990285[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Phase 1
rhPSMA-7.3
Prostate Cancer
Phase 1
Clinical Trials (1)
NCT03995888Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Phase 1
18F-Fluciclovine
Glioma
Phase 1
Clinical Trials (1)
NCT05555550Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Phase 1
18F-fluciclovine
Glioma
Phase 1
Clinical Trials (1)
NCT04114370Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
Phase 1
18F-fluciclovine
Bladder Cancer
Phase 1
Clinical Trials (1)
NCT0401805318Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Phase 1
Clinical Trials (1)
NCT06516510A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Phase 1
18F fluciclovine
Brain Metastases
Phase 1
Clinical Trials (1)
NCT0604809418F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Phase 1
flotufolastat F 18
Prostate Cancer
Phase 1
Clinical Trials (1)
NCT07069465Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging
Phase 1
18F fluciclovine
Brain Metastases, Adult
Phase 1
Clinical Trials (1)
NCT04689048Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Phase 1
18F-Fluciclovine PET-MRI
Glioma
Phase 1
Clinical Trials (1)
NCT0555304118F-Fluciclovine PET-MRI in High-grade Glioma
Phase 1
[18F]FLT
Brain Tumor
Phase 1/2
Clinical Trials (1)
NCT03276676[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
Phase 1/2
Arm A: 177Lu rhPSMA-10.1
Prostate Cancer
Phase 1/2
Clinical Trials (1)
NCT06066437NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Phase 1/2
Clinical Trials (1)
NCT07414940ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05413850Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT07432633[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Phase 1/2
Phase 2
Clinical Trials (1)
NCT0415824518F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Phase 2
18F-Fluciclovine
Brain Metastases
Phase 2
Clinical Trials (1)
NCT05554302Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Phase 2
Phase 2
Clinical Trials (1)
NCT07285057Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Phase 2
PET/CT with F-Fluciclovine
Brain Tumor, Recurrent, Adult
Phase 2
Clinical Trials (1)
NCT0392567518F-Fluciclovine PET and Multiparametric MR Imaging
Phase 2
18F-Fluciclovine
Brain Metastases
Phase 2
Clinical Trials (1)
NCT06055790Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
Phase 2
Computed Tomography
Prostate Carcinoma
Phase 2
Clinical Trials (1)
NCT07185165An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
Phase 2
PET/CT, PET/MRI, mpMRI
Prostate Carcinoma
Phase 2
Clinical Trials (1)
NCT02002455Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI
Phase 2
Positron Emission Tomography
Prostate Adenocarcinoma
Phase 2
Clinical Trials (1)
NCT04175431Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Phase 2
Clinical Trials (1)
NCT07393867Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Phase 2
Fluciclovine PET guided Radiotherapy
Newly Diagnosed Glioblastoma
Phase 2
Clinical Trials (1)
NCT04840069Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
Phase 2
18F fluciclovine
Brain Metastases
Phase 2
Clinical Trials (1)
NCT06617481PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Phase 2
Leuprolide
Prostate Cancer
Phase 2
Clinical Trials (1)
NCT07455903Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Phase 2
18F-Fluciclovine
Prostate Cancer
Phase 2
Clinical Trials (1)
NCT03263780High Resolution PET-MRI Before Prostate Cancer HIFU
Phase 2
Phase 2
Clinical Trials (1)
NCT05779943Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
Phase 2
FACBC PET-CT
Prostate Cancer
Phase 2
Clinical Trials (1)
NCT02830880FACBC Prostate Therapy Response
Phase 2
rhPSMA-7.3
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT04186819Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Phase 3
18F-Labeled Positron Emission Tomography
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT05678322Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
Phase 3
F-Fluciclovine radiotracer
Brain Metastasis
Phase 3
Clinical Trials (1)
NCT0615933518F-FLUC PET/MR in Patients With Brain Mets
Phase 3
rhPSMA-7.3
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT04186845Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Phase 3
18F fluciclovine
Brain Metastases
Phase 3
rhPSMA-7.3
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT05799248Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Phase 3
18F-fluciclovine PET CT
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT0268004118F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
Phase 3
PET imaging with 18F fluciclovine
Grade III or Grade IV Glioma
Phase 3
Clinical Trials (1)
NCT0547913618F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 48 clinical trials

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles